Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Urothelial03 in previously treated locally advanced or metastatic urothelial carcinoma
2024-516906-47-00Phase 3Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan, gemcitabine, carboplatin and cisplatin in transitional cell carcinoma (TCC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Planned start Nov 2025; status: authorised.
02
Drugs
datopotamab deruxtecangemcitabinecarboplatincisplatin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-516906-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516906-47-00.